By Professor David Dang Fung Ma

Journal articles

Connor DE; Joseph JE; Baron D; Muller DW; Roy P; Wilson S; Ma DD, 2003, 'Abciximab therapy post elective coronary artry stenting does not prevent a troponin rise mediated by increased levels of platelet P-selectin an dplatelet-monocyte aggregates', Journal of Thrombosis and Haemostasis, pp. 1769 - 1769

Exner T; Joseph JE; Low J; Connor DE; Ma DD, 2003, 'Detection of procoagulants with a more reliable nonactivated clotting test', Journal of Thrombosis and Haemostasis, pp. 1598 - 1598

Tao H; Ma DD, 2003, 'Evidence for transdifferentiation of human bone marrow-derived stem cells: Recent progress and controversies', Pathology, 35, pp. 6 - 13

Moore JJ; Milliken ST; Ma DD; Biggs JC, 2003, 'Letter to the Editor CD34 selected versus unmanipulated grafts for severe rheumatoid arthritis: Reply', Arthritis Care & Research, 48, pp. 1464 - 1466

Exner T; Joseph JE; Low J; Connor DE; Ma DD, 2003, 'Procoagulant phospholipid in blood normally associates mainly with cells or aggregates larger than microparticles or platelets', Journal of Thrombosis and Haemostasis, pp. 1078 - 1078

Hui CH; Goh K; White D; Branford S; Grigg A; Seymour JF; Kwan YL; Walsh S; Hoyt R; Trickett A; Rudzki B; Ma DD; To LB; Hughes TP, 2003, 'Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR', Leukemia, 17, pp. 821 - 828

Moore JJ; Brooks P; Milliken ST; Biggs JC; Ma DD; Handel ML; Will R; Rule S; Joske D; Langlands B; Taylor K; O Callaghan J; Szer J; Wicks I; McColl GJ; Passeullo F; Snowden J, 2002, 'A pilot randomised trial comparing CD34 selected versus unmanipulated haemopoietic stem cell transplanation for severe resistant rheumatoid arthritis', Arthritis Care & Research, 46, pp. 2301 - 2309

Tao H; Rao RS; Ma DD, 2002, 'Transdifferentiation of human haemopoetic lineage negative bone marrow cells to neural cells by cotokines and chemical inducing agent', Blood, 100, pp. 159

Aboud M; Ma DD, 2001, 'Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance', Clinical and Laboratory Haematology, 23, pp. 411 - 416

Matthews JP; Bishop JF; Young G; Juneja SK; Lowenthal RM; Garson OM; Cobcroft RG; Dodds AJ; Enno A; Gillett EA; Hermann RM; Joshua DE; Ma DD; Szer J; Taylor KM; Wolfe M; Bradstock KF, 2001, 'Patterns of failure with increasing intensification of induction chemotherapy for acute myeloid leukaemia', British Journal of Haematology, 113, pp. 727 - 736

Moore JJ; Milliken ST; Ma DD; Briggs JW; Brooks P, 2001, 'Peripheral blood stem cell transplantation for rheumatoid arthritis - Australian experience', Journal of Rheumatology, 28, pp. 8 - 12

Mills AK; Taylor KM; Wright SJ; Bunce LH; Bashford J; White K; McLennon R; Ma D; Szer J; Fitzsimmons AJ, 2000, 'Poor yields of peripheral blood stem cells following chlorodeoxyadenosine (2CDA) and VAC treatment for poor-risk, de-novo follicular nonhodgkins lymphoma', Blood, 96

Mills AK; Taylor KM; Wright SJ; Bunce LH; Bashford J; White K; McLennan R; Miles Prince H; Hertzberg M; Ma DF; Kelly CM; Fitzsimmons AJ, 2000, 'Sustained responses following alternating chlorodeoxyadenosine (2CDA) and VAC regimen in poor-risk de-novo follicular non-hodgkin's lymphoma (NHL)', Blood, 96

Moore J; Aboud M; Ma D, 2000, 'Adult transient lupus anticoagulant patients maintain an acquired activated protein C resistance profile', Thrombosis and Haemostasis, 84, pp. 735 - 736, http://dx.doi.org/10.1055/s-0037-1614103

Ma DDF; Rede T; Naqvi NA; Cook PD, 2000, 'Synthetic oligonucleotides as therapeutics: The coming of age', Biotechnology Annual Review, 5, pp. 155 - 196, http://dx.doi.org/10.1016/S1387-2656(00)05035-3

Aboud MR; Ma DDF, 1999, 'Increased incidence of venous thromboembolism in patients with shortened APTT and low APC resistance ratio', THROMBOSIS AND HAEMOSTASIS, pp. 777 - 777, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000085665902466&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ma DDF; Cheong KF; Wong K; Sheather K; Coyle L, 1999, 'Polymorphism of factor V, MTHFR, PAI-1 and prothrombin in patients with venous thromboembolism', THROMBOSIS AND HAEMOSTASIS, pp. 655 - 655, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000085665902076&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Pecheniuk NM; Cheong KF; Marsh NA; Walsh TP; Ma DDF, 1999, 'Use of the first nucleotide change (FNC) technology to detect Factor V Leiden, prothrombin 20210 and methylene tetrahydrofolate reductase variants in patients with venous thrombosis and coronary artery disease', THROMBOSIS AND HAEMOSTASIS, pp. 666 - 666, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000085665902114&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Mackinlay N; Aboud M; Roach V; Isbister J; Ma D, 1999, 'Letters to the Editor [1]', Australian and New Zealand Journal of Obstetrics and Gynaecology, 39, pp. 138, http://dx.doi.org/10.1111/j.1479-828X.1999.tb03468.x

Kossard S; Ma DD, 1999, 'Acral keratotic graft versus host disease simulating warts', Australasian Journal of Dermatology, pp. 161 - 163

Naqvi N; Rede T; Bonifacio M; Ma DD, 1999, 'Quantitative analysis of porphyrin-linked oligonucleotides and their biodegraded products by capillary gel electrophoresis using multiple wavelengths', Analytical Biochemistry, pp. 426 - 427

Mackinlay N; Aboud M; Roach V; Isbister J; Ma DD, 1999, 'Resistance to activated protein c in pregnancy and preclampsia', Australian and New Zealand Journal of Obstetrics and Gynaecology, pp. 138 - 139

Turtle CJ; Keefe DM; Bell DJ; Wheeler H; Ma DD, 1999, 'Severe adverse reaction to high epirubicin and cyclosphamide for poor prognosis breast cancer', Australian and New Zealand Journal of Medicine, pp. 275 - 277

Coiffier B; Haioun C; Ketterer N; Engert A; Tilly H; Ma D; Johnson P; Lister A; Feuring-Buske M; Radford JA; Capdeville R; Diehl V; Reyes F, 1998, 'Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study', Blood, 92, pp. 1927 - 1932

Moore J; Ma DDF; Concannon A, 1998, 'Non-malignant bone marrow necrosis: A report of two cases', Pathology, 30, pp. 316 - 318, http://dx.doi.org/10.1080/00313029800169526

Moore J; Ma DD; Concannon A, 1998, 'Non-malignant bone marrow necrosis: a report of two cases.', Pathology, 30, pp. 318 - 320, http://dx.doi.org/10.1080/00313029800169536

Evans J; Percy J; Eckstein R; Ma D; Schnitzler M, 1998, 'Surgery for intestinal graft-versus-host disease: Report of two cases', Diseases of the Colon and Rectum, 41, pp. 1573 - 1576, http://dx.doi.org/10.1007/BF02237309

Hughes TP; Grigg A; Szer J; Ho J; Ma D; Dale BM; Green RM; Norman JE; Sage RE; Herrmann R; Cannell P; Schwarer AP; Taylor K; Atkinson K; Arthur C, 1997, 'Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: Correlation with Sokal prognostic index and haematological control', British Journal of Haematology, 96, pp. 635 - 640, http://dx.doi.org/10.1046/j.1365-2141.1997.d01-2068.x

Aboud MR; Ma DDF, 1997, 'A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation', British Journal of Haematology, 97, pp. 798 - 803, http://dx.doi.org/10.1046/j.1365-2141.1997.1432958.x

Le Doan T; Étoré F; Ma DDF; Tenu JP, 1996, 'Perspectives d'une chimiothérapie plus sélective avec les oligonucléotides antisens', Annales de Medecine Interne, 147, pp. 542 - 552

Arthur CK; Enno A; Firkin F; Ma D; Iland H; Concannon A; Young G; Shaw P; Gallo J; Hertzberg M, 1996, 'A dose escalation study of high dose interferon alpha 2a (HDIFN) up to 18 million units daily in patients with poor prognosis chronic myeloid leukemia (CML) or good prognosis patients who have failed treatment with IFN plus cytosine arabinoside (ARA-C)', BLOOD, 88, pp. 2291 - 2291, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1996VT98302291&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hughes TP; Grigg A; Szer J; Ho J; Ma D; Dale BM; Green RM; Norman JE; Sage RE; Herrmann R; Cannell P; Schwarer AP; Taylor K; Atkinson K; Arthur C, 1996, 'Mobilization of predominantly Ph-negative blood progenitors using cyclophosphamide and lenograstim in early chronic phase CML: Correlation with Sokal prognostic index and hematological control pre-mobilisation.', BLOOD, 88, pp. 927 - 927, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1996VT98300927&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Ma DDF; Wei AQ, 1996, 'Enhanced delivery of synthetic oligonucleotides to human leukaemic cells by liposomes and immunoliposomes', Leukemia Research, 20, pp. 925 - 930, http://dx.doi.org/10.1016/S0145-2126(96)00062-8

Chang A; Ma DDF, 1996, 'An Australian multi-centre study assessing the variability of CD34+ cell measurement for PB stem cell transplantation', BRITISH JOURNAL OF HAEMATOLOGY, 93, pp. 907 - 907, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1996UP11400907&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Straetmans N; Ma DDF; Nevell DF; Arthur C, 1996, 'Evolution of bone marrow fibrosis and stromal antigenic expression in chronic myeloid leukemia on alpha interferon and Ara-c therapy', HEMATOPATHOLOGY AND MOLECULAR HEMATOLOGY, 10, pp. 213 - 222, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1996WG50400005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Chang A; Ma DDF, 1996, 'The influence of flow cytometric gating strategy on the standardization of CD34+ cell quantitation: An Australian multicenter study', Journal of Hematotherapy and Stem Cell Research, 5, pp. 605 - 616, http://dx.doi.org/10.1089/scd.1.1996.5.605

Chang A; Ma DD, 1996, 'The influence of flow cytometric gating strategy on the standardization of CD34+ cell quantitation: an Australian multicenter study. Australasian BMT Scientists Study Group.', J Hematother, 5, pp. 605 - 616, http://dx.doi.org/10.1089/scd.1.1996.5.605

Straetmans N; Ma DDF; Herman P; Zenebergh A; Chang A; Deneys V; De Bruyere M; Ferrant A, 1995, 'Long-term culture of autologous transplanted bone marrow for acute myeloid leukaemia: Evidence for an in vitro haemopoietic defect and lack of correlation with the speed of engraftment', Bone Marrow Transplantation, 15, pp. 421 - 428

Ma DDF; Aboud MR; Williams BG; Isbister JP, 1995, 'Activated protein c resistance (APC) and inherited factor V (FV) mis‐sense mutation in patients with venous and arterial thrombosis in a haematology clinic', Australian and New Zealand Journal of Medicine, 25, pp. 151 - 154, http://dx.doi.org/10.1111/j.1445-5994.1995.tb02828.x

Yin J; Williams BG; Arthur CK; MA DDF, 1995, 'Interferon response in chronic myeloid leukaemia correlates with ABL/BCR expression: a preliminary study', British Journal of Haematology, 89, pp. 539 - 545, http://dx.doi.org/10.1111/j.1365-2141.1995.tb08361.x

Gala JL; Noël H; Rodhain J; Ma DFF; Ferrant A, 1995, 'P-glycoprotein positive, drug resistant invasive lymphoepithelial thymoma: Treatment response to chemotherapy with cyclosporin and quinine', Journal of Clinical Pathology, 48, pp. 679 - 681, http://dx.doi.org/10.1136/jcp.48.7.679

MA DDF; ARTHUR CR; YIN JL; WILLIAMS BG, 1994, 'COMBINED ALFA-INTERFERON AND LOW-DOSE ARA-C THERAPY FOR CHRONIC MYELOID-LEUKEMIA AND CORRELATION OF ABL BCR TRANSCRIPT WITH RESPONSE TO INTERFERON', BLOOD, 84, pp. A153 - A153, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1994PR75400596&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

MA DDF; WILLIAMS BG; ABOUD MR; ISBISTER JP, 1994, 'FACTOR-V MISSENSE MUTATION AND APC-RESISTANCE IN PATIENTS WITH VENOUS THROMBOEMBOLISM', BLOOD, 84, pp. A84 - A84, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1994PR75400322&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

GALA JL; FERRANT A; MA D; MARTIAT P; DOVEN C; DELANNOY A; MICHAUX JL, 1994, 'INTRACYTOPLASMIC LOCALIZATION (ICL) OF P-GLYCOPROTEIN (GP-170) AS A PROGNOSTIC FACTOR IN DE-NOVO ACUTE MYELOBLASTIC-LEUKEMIA (AML)', BLOOD, 84, pp. A618 - A618, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1994PR75402453&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Williams BG; Yin JL; Ma DDF, 1994, 'A ph⁺ acute myeloid leukaemia expressing both CML-type and ALL-type BCR/ABL mRNA transcripts', Leukemia and Lymphoma, 14, pp. 341 - 346, http://dx.doi.org/10.3109/10428199409049688

Ma DDF; Le Doan T, 1994, 'Antisense oligonucleotide therapies: Are they the 'magic bullets'?', Annals of Internal Medicine, 120, pp. 161 - 162, http://dx.doi.org/10.7326/0003-4819-120-2-199401150-00010

Galettis P; Boutagy J; Ma DDF, 1994, 'Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia', British Journal of Cancer, 70, pp. 324 - 329, http://dx.doi.org/10.1038/bjc.1994.301

Gala JL; McLachlan JM; Bell DR; Michaux JL; Ma DDF, 1994, 'Specificity and sensitivity of immunocytochemistry for detecting P-glycoprotein in haematological malignancies', Journal of Clinical Pathology, 47, pp. 619 - 624, http://dx.doi.org/10.1136/jcp.47.7.619

Bishop JF; Matthews JP; Young G; Szer J; Joshua DE; Dodds A; Laidlaw CR; Cobcroft R; Herrman R; Ma D; Page FJ, 1994, 'The influence of induction chemotherapy dose and dose intensity on the duration of remission in acute myeloid leukemia', Leukemia and Lymphoma, 15, pp. 79 - 84, http://dx.doi.org/10.3109/10428199409051681

CARTWRIGHT KD; ARTHUR CK; MA DDF; ISBISTER JP, 1993, 'SHORT INTENSIVE CHEMOTHERAPY (COPE COMP) FOR INTERMEDIATE AND HIGH-GRADE NON-HODGKINS-LYMPHOMA', BLOOD, 82, pp. A561 - A561, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:A1993MJ68202227&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page